Overview
Overview
웹리포트
Innovative Products From Schering Complement Bayer HealthCare’s Successful Portfolio
From birth-control pills to cancer therapies
|
| In vitro testing: Cam Quoc examines ovum-cumulus complexes. Cumulus cells form layers around the ovum and play an important role in oocyte maturation. |
The acquisition of Schering was the largest take-over in Bayer’s history. Under the name Bayer Schering Pharma AG, Germany* , the joint pharmaceutical company is now aiming to become one of the largest players on the world market. Schering brings with it an extensive range of products in the fields of gynecology and andrology, diagnostic imaging, oncology and specialized therapeutics which ideally complement Bayer’s existing portfolio.
"Our goal is to make the future Bayer Schering Pharma AG, Germany* a strong company that ranks among the top ten pharmaceutical specialists in the world." This is how Werner Wenning, Chairman of Bayer's Board of Management, envisages the future of the new company which aims to set new standards in research and development. Like Bayer, Schering has much to offer in this area and will thus strengthen the activities of Bayer HealthCare's Pharmaceuticals Division.
Schering stands for innovation based on tradition: Schering has been actively engaged in research and development at the cutting edge of science ever since the "Green Pharmacy" was founded by Ernst Schering 155 years ago, and today is still tackling the challenges posed by medicine. Schering has been the world leader for years now with numerous products.
"Our goal is to make the future Bayer Schering Pharma AG, Germany* a strong company that ranks among the top ten pharmaceutical specialists in the world." This is how Werner Wenning, Chairman of Bayer's Board of Management, envisages the future of the new company which aims to set new standards in research and development. Like Bayer, Schering has much to offer in this area and will thus strengthen the activities of Bayer HealthCare's Pharmaceuticals Division.
Schering stands for innovation based on tradition: Schering has been actively engaged in research and development at the cutting edge of science ever since the "Green Pharmacy" was founded by Ernst Schering 155 years ago, and today is still tackling the challenges posed by medicine. Schering has been the world leader for years now with numerous products.
Schering – the world market leader in hormonal contraceptives for women
The best example of this is the birth-control pill, which many women regard as synonymous with Schering. After all, it was the Berlin-based company which introduced the first oral contraceptive to the European market in 1961. A milestone on the path to self-determined family planning which cemented the company's reputation as a hormone specialist.
Today Schering is the world market leader in hormonal contraceptives for women - in terms of both units sold and revenue. In addition to various birth-control pills, the extensive product portfolio also includes implants, injections and intrauterine devices, used and trusted by over seven million women around the world.
Professor Ursula-Friederike Habenicht, head of Gynecology and Andrology Research, and her team are already working on the contraceptives of tomorrow. Thanks to molecular biology, it is possible to understand how the processes in the human body work right down to the molecular level. "This opens the door to entirely new possibilities, such as the targeted suppression of sperm maturation in the epididymis. New developments are also happening in female contraception, and we are looking for other safe alternatives for women," says Habenicht.
Today Schering is the world market leader in hormonal contraceptives for women - in terms of both units sold and revenue. In addition to various birth-control pills, the extensive product portfolio also includes implants, injections and intrauterine devices, used and trusted by over seven million women around the world.
Professor Ursula-Friederike Habenicht, head of Gynecology and Andrology Research, and her team are already working on the contraceptives of tomorrow. Thanks to molecular biology, it is possible to understand how the processes in the human body work right down to the molecular level. "This opens the door to entirely new possibilities, such as the targeted suppression of sperm maturation in the epididymis. New developments are also happening in female contraception, and we are looking for other safe alternatives for women," says Habenicht.
Bookmark this page
E-mail this page
Advanced search
